Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma

• Main Author: R Nandha
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2012-01-01
• Series: Journal of Postgraduate Medicine
• Subjects: 17 α hydroxylase and c17; 20 lyase inhibitors; abiraterone acetate; castration-resistant prostate carcinoma
• Online Access: http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2012;volume=58;issue=3;spage=203;epage=206;aulast=Nandha
• ISSN: 0022-3859; 0972-2823

Androgen-deprivation therapy is the mainstay of treatment for the management of advanced prostate carcinoma till transition to castration-resistant prostate carcinoma (CRPC). Recently, adrenal and intratumoral synthesis of androgens has been found to be the major cause for CRPC. Abiraterone acetate is an orally active, potent and selective inhibitor of 17 a hydroxylase and c 17, 20 lyase, which acts by decreasing the de novo production of androgens with no rise in steroids downstream. Multiple randomized trials have shown significant improvement of >50% decline in prostate-specific antigen (PSA) and time to PSA progression (TTPP) with abiraterone acetate 1000 mg per day in chemotherapy/ketoconazole treated and naive CRPC patients producing reversible and manageable adverse effects due to mineralocorticoid excess. This article reviews the available evidence on efficacy and safety of this drug in CRPC. Searches of Pubmed, Cochrane database, Medscape, Google and clinicaltrial.org were made for terms like CRPC and abiraterone.